Description

This Webinar will focus on evidence that sodium-glucose-linked cotransport inhibitors (SGLT2i) reduces the development of end-stage kidney disease (ESKD), cardiovascular events, including heart failure and cardiac death in diabetic and non-diabetic patients, with and without chronic kidney disease.